BPC-157 Injection Site: Body Locations in Research

The location of BPC-157 injections in the literature is determined by the design of the experiment and the area of focus. It is common to see that studies involving rodents use the belly for the injection. For experimentations targeting specific injuries, subcutaneous and intramuscular areas are often chosen. Another technique is the localized delivery which involves injecting the area around the affected area. As seen below, the researchers have examined scholarly literature pertaining to the injection areas of BPC-157 in animal studies only.

Injection Sites Used in BPC-157 Research

Abdominal Cavity (Intraperitoneal)

The most frequently used route of administration in research involving BPC-157 is the intraperitoneal. The needle is inserted into the lower left side of the rat’s abdomen where the peptide is released into the peritoneal cavity. The peptide is absorbed via the mesenteric blood vessels into the portal circulation. This method provides prompt systemic absorption and is easy to perform in small animals. As noted bySeiwerth et al. review (2018), intraperitoneal route is widely used in the majority of published studies on BPC-157.

Intraperitoneal injection refers to a laboratory method which is not used for clinical purposes in people. The absorption kinetics from the peritoneal cavity are different than those for subcutaneous or intramuscular injection. Because of this, it cannot be assumed that data from studies in which intraperitoneal injection was used can also be applied to other injection sites.

Subcutaneous Sites

The peptides are injected with the help of injections underneath the skin. The subcutaneous injections are often given in the skin on the back of rodents, causing the absorption of peptides comparatively slowly compared to IP. Some studies with BPC-157 have used this method of injection when questions concerning a specific body region were involved in the study.

Intramuscular Locations

Intramuscular injection places the solution directly into muscle tissue. In rats, the quadriceps or gastrocnemius muscles are typical targets. The Novinscak et al. muscle crush study used IP injection rather than IM, even though the target was muscle tissue. IM injection in small rodents is technically challenging due to limited muscle mass. It appears less frequently in the BPC-157 literature than IP or subcutaneous routes.

Local Administration Near Injury

A number of studies have directly administered BPC-157 into the target site of injury. The Chang et al. tendon study injected a dose of the peptide at the site. The advantage of local administration is that a high concentration can be achieved exactly where it matters. This is due to pharmacology, since bypassing general distribution means getting the best possible quality of local exposure. Whether this produces better outcome than a systemic injection had not been tested in a comparative fashion.

Site Selection Rationale in Study Design

Local vs Systemic Injection

Does Injection Location Affect Outcome?

There has been no controlled comparison to answer this question. Both systemic IP injections and local injections showed positive results in their respective studies. The Staresinic study on muscle crush used systemic IP injection and saw muscle recovery. The Chang study on tendons used local injection and saw tendon repair. However, these are different models of injury, types of tissues, and methods of measurement. Comparing these results does not show one method to be better than the other.

It is easy to understand the rationale behind localised injections that according to the principle, a higher concentration in the injury area would provide a stronger impact on the localised tissue. However, it has been proven that systemic injections can also be effective even at sites that are quite far from the point of injection. For instance, although BPC-157 was injected intraperitoneally, it influenced tendon repair and nerve function.

Systemic Distribution After Local Injection

Peptides injected locally do not stay at the injection site. They diffuse through surrounding tissue and enter the lymphatic and vascular systems. The rate of clearance from the injection site depends on the peptide's molecular weight, charge, lipophilicity and local blood flow. BPC-157 is a 15-amino-acid peptide with relatively low molecular weight. It will redistribute after local injection. The question is how much remains at the target tissue and for how long. We found no published pharmacokinetic study measuring BPC-157 tissue concentrations after local versus systemic injection.

Body Sites Discussed in Online Communities

Shoulder and Knee Discussions

There are many online forums and community discussions that mention subcutaneously injecting BPC-157 into the area around the injured shoulders and knees. The logic of these injections is based on the local injection logic advocated in the scientific literature, which recommends injecting close to the site of injury to get the best local concentration. These reports are merely experiential; they do not have controls, standardized dosages, verified product purity, and objective measurements of results. The purpose of this section of the document is to state what has been discussed in the community, rather than to prove that the methodology is correct.

Abdominal Fat Pad

The abdominal fat pad is another frequently-mentioned location in community forums for subcutaneous injection. It closely mirrors the subcutaneous research method used in animal studies but is on the human level. Most individuals have a fairly uniform thickness of subcutaneous fat in the lower abdomen, making self-injection a possibility. No studies to date have compared the effect of subcutaneous injections of BPC-157 in the abdomen to other sites in any species.

Why Community Practices Differ from Study Methods

There is a large gap separating research techniques from community practices. In research, IP injection is being used, while in communities, subcutaneous injection is used. There are differences in anatomical sites. The pharmacokinetics are different and the products are different (research quality products vs. Commercial products with varying quality). The outcome measures are also different (histological endpoints vs. Subjective pain report). In order to draw conclusion about injection sites in humans based on rodent IP data, many assumptions must be made, which cannot be verified at this time. For more information on techniques, please refer to our injection guide.